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DATA NOTE
Oxford Screening CSF and Respiratory 
samples (‘OSCAR’): results of a pilot study 
to screen clinical samples from a diagnostic 
microbiology laboratory for viruses using 
Illumina next generation sequencing
Colin Sharp1,2†, Tanya Golubchik3,4†, William F. Gregory1, Anna L. McNaughton5, Nicholas Gow6, 
Mathyruban Selvaratnam6, Alina Mirea6, Dona Foster7, Monique Andersson6, Paul Klenerman5,6, Katie Jeffery6 
and Philippa C. Matthews5,6* 
Abstract 
Objectives: There is increasing interest in the use of metagenomic (next generation sequencing, NGS) approaches 
for diagnosis of infection. We undertook a pilot study to screen samples submitted to a diagnostic microbiology 
laboratory in a UK teaching hospital using Illumina HiSeq. In the short-term, this small dataset provides insights into 
the virome of human respiratory and cerebrospinal fluid (CSF) samples. In the longer term, assimilating metagenomic 
data sets of this nature can inform optimization of laboratory and bioinformatic methods, and develop foundations 
for the interpretation of results in a clinical context. The project underpins a larger ongoing effort to develop NGS 
pipelines for diagnostic use.
Data description: Our data comprise a complete metagenomic dataset from 20 independent samples (10 CSF and 
10 respiratory) submitted to the clinical microbiology laboratory for a large UK teaching hospital (Oxford University 
Hospitals NHS Foundation Trust). Sequences have been uploaded to the European Nucleotide Archive and are also 
presented as Krona plots through which the data can be interactively visualized. In the longer term, further optimiza-
tion is required to better define sensitivity and specificity of this approach to clinical samples.
Keywords: Metagenomics, Next generation sequencing, Illumina, Diagnosis, Virome, Microbiome, Infection, 
Respiratory, CSF
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Objective
Next generation sequencing (NGS) is an attractive 
approach to diagnosis of infection, with the potential to 
offer a single diagnostic pipeline to identify viruses, bac-
teria and fungi from a range of clinical samples [1–4]. 
However, there are multiple challenges in implementing 
such systems, and ongoing efforts are required to develop 
in  vitro methods for handling diverse types of clinical 
samples, evaluate and improve sensitivity, reduce the 
high burden of human reads, distinguish contaminants 
or commensals from pathogenic organisms, and optimise 
positive and negative controls.
In this small pilot study, we focused on the detection 
of viruses from cerebrospinal fluid (CSF) and respiratory 
samples submitted to a routine diagnostic microbiology 
laboratory in order to evaluate a methods protocol and 
to provide a preliminary dataset for analysis, with a view 
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to optimizing our laboratory approach and providing a 
foundation for improving bioinformatic algorithms.
A summary of this work was presented at the UK 
National Federation of Infection Societies (FIS) meeting, 
Birmingham, November 2017 [5]. We have subsequently 
focused specific attention on analysis of human herpes 
virus 6 (HHV-6) reads from within these samples, as this 
provides an interesting example of an organism which is 
widespread, potentially pathogenic [6–8] but may also 
be a bystander in clinical samples [9]. These results and 
analysis are presented in a separate manuscript [10].
Data description
Sample cohort
We randomly selected 10 cerebrospinal fluid (CSF) 
and 10 respiratory samples (20 different patients repre-
sented). CSF samples were submitted to the clinical diag-
nostic laboratory at Oxford University Hospitals NHS 
Foundation Trust between November 2012 and May 
2014, and respiratory samples between May and Decem-
ber 2014. Prior to use for this research, samples had 
undergone routine clinical laboratory testing and were 
then stored at − 80 °C.
In vitro methods
A full description of laboratory methods is provided in 
linked data files (see ‘OSCAR protocol’ listed in Table 1). 
In brief, samples were filtered through 0.45 μm spin col-
umn filters (Merck Millipore) to remove large cellular 
debris and bacterial contaminants. To increase the rela-
tive amount of encapsidated viral to host nucleic acids in 
the sample, we pre-treated the sample with DNAse and 
RNAse. Nucleic acids were extracted using the QiaAmp 
MinElute Virus Spin Kit (Qiagen) and recovered in 
nuclease-free water. Reverse transcription was primed by 
random hexamer primers and performed using Super-
Script III reagents. Sequence independent amplification 
of cDNA (and DNA also carried over during extraction) 
was carried out by an initial addition of random octamer 
containing primer sequences. Subsequent PCR was per-
formed using a single primer amplification. Illumina 
Nextera XT libraries were made from amplified cDNAs 
according to the manufacturer’s protocol and sequenced 
on the HiSeq 4000 platform with 150-base paired end 
reads at the Centre for Genomic Research (CGR), Uni-
versity of Liverpool, UK.
Bioinformatic analysis
A full description of laboratory methods is provided 
in linked data files (OSCAR protocol; see description 
and link in Table 1). In brief, the raw FASTQ files were 
trimmed to remove adapter sequences and to remove 
low quality bases. After trimming, reads < 20 base pairs 
were removed. The remaining reads were classified using 
Kraken v0.10.5-beta [11] against a reference database 
comprising the human genome in combination with 
all RefSeq genomes for viruses, bacteria and archaea. 
Human-tagged reads were discarded and the remainder 
were taken forward for analysis.
We used Kaiju [12] to confirm that the Kraken analy-
sis was complete, using the full Genbank non-redundant 
protein database for viruses, bacteria and archaea. Reads 
were assembled de novo using metaSPAdes v3.10 [13, 
14]. Assembled contigs were classified with Kraken [11], 
and results were visualised with Krona [15].
Limitations
This study was undertaken as a pilot exercise to underpin 
refinement of both laboratory methods and analysis of 
metagenomic data from clinical samples. On the grounds 
of cost, we were restricted to analysis of a small number 
of samples. We did not set out to derive definitive clinical 
diagnosis, and the data should not be used for this pur-
pose. There are inherent difficulties with using residual 
clinical samples, including bias introduced into sample 
selection (e.g. samples from patients with a high pre-test 
probability of infection tend to be used up in primary 
clinical testing and not available for research). In archived 
samples, the quality of nucleic acid may deteriorate over 
time (this may be especially pertinent for RNA viruses).
Our methods did not include positive and negative 
controls. For this reason, it is difficult to assess the sen-
sitivity with which we detected any specific virus; it is 
possible that the in vitro methods may have enriched or 
depleted particular organisms or groups of organisms. In 
future, positive controls can be added by spiking samples 
with an organism that we anticipate would not be present 
in human samples, or running a parallel multiplex con-
trol panel [16].
Future studies, and an accumulation of practical expe-
rience, will be required to increase the certainty with 
which results of NGS platforms can be interpreted. 
While we anticipate instances in which a specific organ-
ism can be identified from a metagenomic dataset as the 
cause of a clinical syndrome, there are many instances 
in which ambiguity may arise as a result of the difficul-
ties in discriminating between pathogenic organisms and 
contaminants or bystanders. Detailed prospective studies 
enrolling large numbers of study subjects are the ultimate 
aspiration, with the aim of collecting high resolution data 
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that include medical history, other laboratory results, 
imaging, treatment and follow-up data.
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